Brief: Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability And Safety Results From Phase 1 Trial Of Sts101 At Multiple Dose Strengths
16/06/2021 22:17
June 16 (Reuters) - Satsuma Pharmaceuticals Inc STSA.O :
* SATSUMA PHARMACEUTICALS ANNOUNCES POSITIVE
PHARMACOKINETIC,
TOLERABILITY AND SAFETY RESULTS FROM PHASE 1 TRIAL OF STS101 AT
MULTIPLE DOSE STRENGTHS
* SATSUMA PHARMACEUTICALS - ALL 3 DOSE STRENGTHS OF STS101,
ADMINISTERED WITH IMPROVED 2ND-GENERATION NASAL DELIVERY DEVICE
WERE WELL-TOLERATED
* SATSUMA PHARMACEUTICALS INC - INITIATING SUMMIT PHASE 3
EFFICACY
TRIAL TO EVALUATE STS101 5.2 MG IN ACUTE TREATMENT OF MIGRAINE
ATTACKS
* SATSUMA PHARMA - ALL 3 DOSE STRENGTHS OF STS101,
ADMINISTERED
WITH IMPROVED 2ND-GENERATION NASAL DELIVERY DEVICE ACHIEVED
TARGET PHARMACOKINETIC PROFILE
Source text for Eikon: ID:nGNXc0Y77W
Further company coverage: STSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Satsuma Pharmaceuticals
See all newsBrief: Satsuma Pharmaceuticals Announces FDA Acceptance Of 505(B)(2) NDA For Sts101, A Novel And Investigational Dihydroergotamine Nasal Powder Product For The Acute Treatment Of Migraine
Commencement Of Tender Offer For Satsuma Pharmaceuticals, Inc In U.S.
Brief: Satsuma Pharmaceuticals Says Received Letter Notifying Co Regained Compliance With Nasdaq
U.S. STOCKS ON THE MOVE-Alphabet Inc, BlackRock, Moderna
Satsuma Pharma soars on buyout deal from Japan's Shin Nippon